A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Public ClinicalTrials.gov record NCT04209114. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible
Study identification
- NCT ID
- NCT04209114
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 114 participants
Conditions and interventions
Interventions
- Nivolumab Biological
- Radical cystectomy (RC) Procedure
- Bempegaldesleukin Biological
Biological · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 4, 2020
- Primary completion
- Jun 6, 2023
- Completion
- Jun 6, 2023
- Last update posted
- Jun 26, 2024
2020 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0080 | Gilbert | Arizona | 85234 | — |
| Local Institution - 0136 | Tucson | Arizona | 85724 | — |
| Local Institution - 0029 | La Jolla | California | 92092-0698 | — |
| Local Institution - 0015 | Orange | California | 92868 | — |
| Local Institution - 0002 | Iowa City | Iowa | 52242 | — |
| Local Institution | Rochester | Minnesota | 55905 | — |
| Local Institution - 0006 | New Brunswick | New Jersey | 08903 | — |
| Local Institution - 0004 | Buffalo | New York | 14263 | — |
| Local Institution - 0009 | The Bronx | New York | 10461 | — |
| Local Institution - 0005 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0007 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0139 | Houston | Texas | 77030 | — |
| Local Institution - 0023 | Temple | Texas | 76508 | — |
| Local Institution - 0122 | Gig Harbor | Washington | 98332 | — |
| Local Institution - 0102 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04209114, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04209114 live on ClinicalTrials.gov.